We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against the other stocks that will make you rich in 2025.
What to Expect from the Stock Market in 2025
Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock market in 2025. His analysis reflects cautious optimism, emphasizing potential growth and significant risks. Timmer described 2024 as a “Goldilocks” year for U.S. stock returns, characterized by robust earnings growth and rising valuations. The S&P 500 Index experienced a substantial increase, concluding the year with a gain of approximately 28% as it reached new all-time highs. This performance was driven by strong earnings from major companies, particularly the so-called “Magnificent Seven” stocks whose growth has significantly influenced the overall market dynamics.
READ ALSO: 10 Best Entertainment Stocks To Buy According to Analysts and 11 Best Computer Hardware Stocks to Invest in Right Now.
Looking ahead to 2025, Timmer maintained a bullish stance on stocks but cautioned that investors should not expect returns to match the spectacular gains of the previous two years. He noted that while earnings forecasts remain strong, especially for the mega-cap stocks, valuations are stretched, currently sitting in the 90th percentile historically. This suggests that significant further expansion in price-to-earnings (PE) ratios could lead to a bubble scenario, which he believes is unlikely. He expects continued earnings growth to support stock prices in 2025. However, valuations may limit future growth. Timmer suggests that earnings must drive performance rather than further valuation expansion to avoid a bubble scenario.
With the bull market entering its third year, Timmer describes it as being in “later innings,” indicating increased caution regarding future performance. He also suggested several risks that could potentially impact the market in 2025. For instance, heavy reliance on a few mega-cap stocks poses a risk; if these stocks falter, it could drag down overall market performance despite broader participation from other stocks. Secondly, although he does not foresee a return to the high inflation rates of the past decades, he warns that rising inflation could lead to higher interest rates, which would negatively affect the stock market.
Our Methodology
To compile the list of 10 stocks that will make you rich in 2025, we conducted a consensus. We sifted through various internet rankings to get an initial list of stocks expected to explode in 2025. Next, we sourced analyst sentiment for each stock from CNN and ranked our list in ascending order of the analysts’ projected upside potential for the next twelve months. Please note that the data was recorded on Friday, December 20, 2024.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A scientific researcher holding a petri dish containing a glycoengineered monoclonal antibody.
TG Therapeutics, Inc. (NASDAQ:TGTX)
Analysts Upside Potential: 33.54%
TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company that focuses on developing and selling new treatments for diseases related to B-cells, which are a type of white blood cell important for the immune system. One of their key products is BRIUMVI, which has been approved for treating relapsing forms of multiple sclerosis in adults. This disease affects the central nervous system, causing the immune system to mistakenly attack the protective covering of nerve fibers, called myelin.
During the fiscal third quarter of 2024, TG Therapeutics, Inc. (NASDAQ:TGTX) reported strong growth for BRIUMVI. The drug generated $83.3 million in net sales, reflecting a 15% increase from the previous quarter and a staggering 230% growth year-over-year. Management noted that the uptake of BRIUMVI is exceeding expectations, driven by positive clinical data presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. The data showed that after five years of treatment, 92% of patients were free from disability progression.
TG Therapeutics, Inc. (NASDAQ:TGTX) is working on a subcutaneous version of BRIUMVI, which would allow for at-home administration. This new formulation is expected to open up additional market opportunities and enhance patient convenience. Moreover, management also received FDA clearance to begin studies on azer-cel, a CAR T-cell therapy for autoimmune diseases, targeting a Phase 1 study launch by early next year. Looking ahead, management has raised its full-year revenue guidance for BRIUMVI to a range of $300 million to $305 million. It is one of the 10 stocks that can make you rich in 2025.
Overall TGTX ranks 10th on our list of the stocks that will make you rich in 2025. While we acknowledge the potential of TGTX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TGTX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center